PT  - JOURNAL ARTICLE
AU  - Izoulet, Maxime
TI  - National Consumption of Antimalarial Drugs and COVID-19 Deaths Dynamics: An Ecological Study
AID  - 10.1101/2020.04.18.20063875
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.18.20063875
4099  - http://medrxiv.org/content/early/2020/05/28/2020.04.18.20063875.short
4100  - http://medrxiv.org/content/early/2020/05/28/2020.04.18.20063875.full
AB  - COVID-19 (Coronavirus Disease-2019) is an international public health problem with a high rate of severe clinical cases. Several treatments are currently being tested worldwide. This paper focuses on anti-malarial drugs such as chloroquine or hydroxychloroquine. We compare the dynamics of COVID-19 daily deaths in countries using anti-malaria drugs as a treatment from the start of the epidemic versus countries that do not, the day of the 3rd death and the following 10 days. We then use a ARIMA modeling to realize a short-term forecast of deaths dynamics for each group. We show that the first group have a much slower dynamic in daily deaths that the second group. This ecological study is of course only one additional piece of evidence in the debate regarding the efficiency of anti-malaria drugs, and it is also limited as the two groups certainly have other systemic differences in the way they responded to the pandemic, in the way they report death or in their population that better explain differences in dynamics. Nevertheless, the difference in dynamics of daily deaths is so striking that we believe it is useful to present these results as a clue in the researches about the efficiency of hydroxychloroquine. In the end, this data might ultimately be either a piece of evidence in favor or anti-malaria drugs or a stepping stone in understanding further what other ecological aspects place a role in the dynamics of COVID-19 deaths.Competing Interest Statementno competing interests to declareFunding Statementno external fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the available data referred in the manuscript are in the data availability link below. https://www.data.gouv.fr/fr/datasets/daily-deaths-due-to-covid19-by-countries-classed-by-their-using-or-not-of-antimalaria-drugs/#_